TrialLineage Concept
Pancreatic precursor lesion biology
Pancreatic cancer does not appear suddenly. It develops over years or decades from earlier, precancerous changes in the cells of the pancreas — changes known as precursor lesions. The study of these lesions has reshaped how scientists understand when pancreatic cancer begins, which mutations drive its earliest stages, and why KRAS occupies such a central role in the disease. This page explains what precursor lesion biology is, what it revealed about pancreatic cancer, and how it connects to the scientific lineage behind KRAS-directed therapies now in clinical trials.
In plain language
What are pancreatic precursor lesions?
A precursor lesion is an abnormal change in tissue that is not yet cancer but that can, over time, progress toward cancer. In the pancreas, the best-studied precursor lesions are called pancreatic intraepithelial neoplasias, or PanINs. These are microscopic changes in the cells lining the small ducts of the pancreas. They are graded by severity: PanIN-1 lesions show mild changes, PanIN-2 lesions show moderate changes, and PanIN-3 lesions — sometimes called carcinoma in situ — are one step short of invasive cancer.
The critical insight from precursor lesion biology is that each stage of PanIN progression is associated with the accumulation of specific genetic mutations. KRAS mutations appear very early — already present in low-grade PanIN-1 lesions — and are found in the vast majority of pancreatic ductal adenocarcinomas. This means KRAS mutation is not a late event in pancreatic cancer but an initiating one. Other mutations, such as those in CDKN2A, TP53, and SMAD4, accumulate in later stages, but KRAS is where the molecular story begins.
Key terms
- PanIN (pancreatic intraepithelial neoplasia): the most common type of pancreatic precursor lesion, graded from low-grade (PanIN-1) to high-grade (PanIN-3)
- IPMN (intraductal papillary mucinous neoplasm): a larger, cystic precursor lesion that can be detected on imaging and that carries a variable risk of progression to invasive cancer
- Progression model: the concept that cancer develops through a series of increasingly abnormal stages, each associated with additional genetic alterations
- Initiating mutation: a genetic change present at the earliest detectable stage of a precursor lesion, suggesting it plays a causal role in starting the disease process
- Clonal evolution: the process by which a single mutant cell gives rise to a population of descendants that acquire additional mutations over time
Why it matters
Why precursor lesion biology matters in understanding pancreatic cancer
It established KRAS as the earliest and most universal driver
Before precursor lesion biology, KRAS was known to be mutated in pancreatic cancer, but its precise role in the disease’s origin was less clear. Studies of PanIN lesions showed that KRAS mutations are present at the very earliest detectable stages of precancerous change — well before the tumor becomes invasive. This finding positioned KRAS not just as a feature of pancreatic cancer but as a likely initiating event, strengthening the rationale for targeting it therapeutically.
It provided a framework for how pancreatic cancer develops over time
The progression model — from normal tissue through PanIN-1, PanIN-2, PanIN-3, to invasive cancer — gave scientists a temporal framework for understanding how genetic damage accumulates. KRAS mutation comes first. Inactivation of tumor suppressors like CDKN2A follows. Loss of TP53 and SMAD4 occurs later, associated with higher-grade lesions and invasive disease. This sequence matters because it tells scientists which events initiate the cancer and which events accelerate it — a distinction relevant to both prevention and treatment.
It informs the search for early detection
Pancreatic cancer is usually diagnosed late, when the disease has already spread beyond the pancreas. Precursor lesion biology suggests that there is a window — potentially years or decades — during which the disease exists as a precursor and might be detectable before it becomes lethal. Understanding the molecular and histological features of precursor lesions is essential to efforts to develop biomarkers, imaging strategies, or screening tests that could catch the disease earlier.
Changing the timeline
How precursor lesion biology changed when we think pancreatic cancer begins
The discovery and characterization of PanINs fundamentally altered the scientific view of pancreatic cancer as a disease that emerges suddenly. Instead, it revealed a slow, stepwise molecular process.
Before precursor lesion studies
Pancreatic cancer was largely understood as a disease diagnosed at an advanced stage, with the molecular events leading to it poorly defined. The relationship between early tissue changes and invasive disease was hypothesized but not systematically characterized at the genetic level. There was no widely accepted model for how or when the disease begins at the molecular level.
The progression model emerges
Work by pathologists and molecular biologists — including research groups at Johns Hopkins and other institutions — established the PanIN grading system and mapped the genetic alterations associated with each stage. This created a progression model analogous to the adenoma-carcinoma sequence in colon cancer: a clear, evidence-based path from normal tissue to invasive disease, with defined molecular steps at each transition.
Implications for the present
This progression model is now foundational to how pancreatic cancer research is organized. It guides early-detection research, informs genetically engineered mouse models used in preclinical drug testing, and provides the biological context for why KRAS-directed therapy is considered relevant across the full spectrum of pancreatic cancer — because KRAS mutation is present from the very beginning.
Connection to KRAS, daraxonrasib, and pancreatic cancer research
How precursor lesion biology strengthened the case for targeting KRAS
KRAS as the initiating event
Precursor lesion studies showed that KRAS mutations are present in the majority of even the lowest-grade PanIN lesions. This finding — replicated across multiple research groups and patient cohorts — established KRAS as the most likely initiating mutation in the pancreatic cancer progression sequence. For drug development, this meant that KRAS is not just one of many targets in pancreatic cancer but is the mutation most deeply embedded in the disease’s biology from its origin.
Mouse models built on the progression concept
The understanding of KRAS as an early driver led to the development of genetically engineered mouse models that express mutant KRAS in the pancreas — most notably the KPC model (which combines KRAS and TP53 mutations). These mice develop PanIN lesions that progress to invasive cancer in a way that closely resembles human disease. These models are now standard tools in preclinical testing of pancreatic cancer drugs, including KRAS-directed therapies like daraxonrasib.
The near-universal prevalence of KRAS mutations in pancreatic cancer
Precursor lesion biology contributed to the understanding that KRAS mutations — particularly at codon 12 — are present in approximately 90% or more of pancreatic ductal adenocarcinomas. This is one of the highest mutation frequencies for any oncogene in any cancer type. It means that a drug effective against mutant KRAS would be relevant to the vast majority of patients, not a molecular subgroup. This broad applicability is part of what makes KRAS such a high-priority target in pancreatic cancer research.
Connecting disease biology to therapeutic rationale
The lineage from precursor lesion biology to daraxonrasib is indirect but foundational. Precursor lesion studies established why KRAS matters in pancreatic cancer — not as a peripheral feature but as the molecular event at the root of the disease. This biological rationale is part of what justifies the clinical development of KRAS-directed therapies in a disease where patients have few effective options and the need for molecularly targeted approaches is acute.
Branch points in scientific thinking
How thinking branched within precursor lesion research
The study of pancreatic precursor lesions has not followed a single interpretive path. Several key questions remain actively debated, and the way researchers have approached them has influenced how the field understands pancreatic cancer.
Linear progression vs. branching evolution
Does pancreatic cancer follow a single path, or multiple diverging ones?
The early progression model — PanIN-1 to PanIN-2 to PanIN-3 to invasive cancer — implied a linear sequence. More recent genomic studies suggest that the picture may be more complex: different regions of a single precursor lesion can evolve independently, and some invasive cancers may arise through paths that do not neatly follow the graded PanIN stages. This branching model of clonal evolution has implications for early detection, because it suggests that progression may not always pass through predictable intermediate stages.
PanINs vs. IPMNs as the primary precursor
Which type of precursor lesion is most clinically relevant?
PanINs are microscopic and discovered primarily through pathological examination of tissue. IPMNs are larger cystic lesions that can be detected on imaging in living patients. Both carry KRAS mutations, but they differ in their clinical management implications. A major branch in the field concerns which type of precursor is most tractable for early detection and prevention strategies. IPMNs are clinically identifiable but progress to cancer at variable and difficult-to-predict rates. PanINs are more directly linked to the common form of pancreatic cancer but are usually invisible without surgery or biopsy.
Cell of origin
Which pancreatic cell type gives rise to PanINs and cancer?
A long-standing question in the field is whether PanINs arise from ductal cells, acinar cells that undergo transdifferentiation, or a specific progenitor population. Mouse model studies have provided evidence supporting multiple origins, and the answer may differ depending on context. This question is not purely academic — the cell of origin may influence how the tumor responds to therapies, including KRAS-directed ones, and which precursor stages are most amenable to interception.
Incomplete and debated approaches
Efforts that fell short or remain unresolved — but advanced understanding
Precursor lesion biology has generated important insights but has also encountered limitations. Several lines of investigation have produced ambiguous or partial results that continue to shape the field.
Early detection biomarkers remain elusive
The hope that precursor lesion biology would quickly lead to blood-based or imaging-based early detection tests for pancreatic cancer has not yet been fulfilled. KRAS mutations are detectable in circulating DNA in some settings, but the sensitivity and specificity needed for population-level screening remain insufficient. The biological insight — that there is a long precancerous phase — is sound, but translating it into a practical screening tool has proven extraordinarily difficult.
Chemoprevention strategies have not been validated
The existence of a progression sequence raises the theoretical possibility of chemoprevention — using drugs to prevent precursor lesions from advancing to invasive cancer. In practice, no chemoprevention strategy for pancreatic cancer has been clinically validated. The challenges include identifying who is at risk (most precursor lesions never progress), determining the right intervention point, and justifying the cost and side effects of treatment in people who may never develop cancer.
Grading systems have proven difficult to apply consistently
The PanIN grading system was a conceptual advance, but its application in practice has faced challenges. Pathologists sometimes disagree on the grade of a given lesion, particularly at the boundary between PanIN-1 and PanIN-2. The system has been revised to a simplified two-tier classification (low-grade and high-grade) in part to improve reproducibility. These grading debates reflect the inherent difficulty of imposing discrete categories on a continuous biological process.
The timeline from precursor to cancer remains uncertain
Computational modeling and autopsy studies suggest that the progression from an initiating KRAS mutation to invasive pancreatic cancer may take a decade or more. But these estimates are inferred, not directly observed in living patients, and the timeline almost certainly varies between individuals. The uncertainty about progression speed limits the ability to design interception strategies and makes it difficult to predict which precursor lesions will become dangerous.
What often gets missed
What the public usually does not hear about pancreatic precursor lesion biology
Public awareness of pancreatic cancer focuses almost entirely on the disease after diagnosis — treatment options, survival statistics, and clinical trials. The decades-long biological process that precedes diagnosis is rarely discussed, even though it holds some of the most important clues for both prevention and treatment.
Pancreatic cancer has a long precancerous phase
The public perception of pancreatic cancer as a disease that strikes without warning is understandable given how late it is usually diagnosed. But biologically, the disease develops over many years through identifiable molecular stages. The gap between biological onset and clinical detection is not a reflection of how the disease works — it is a reflection of our current inability to detect it early enough.
KRAS is not just one mutation among many
In public-facing cancer information, KRAS is often listed alongside other mutated genes as though they are equivalent features of the disease. Precursor lesion biology reveals that KRAS mutation is qualitatively different: it appears first, is present in nearly all cases, and is likely the event that initiates the entire disease process. This gives KRAS-directed therapy a biological logic that goes beyond simply targeting the most common mutation.
Most precursor lesions never become cancer
Low-grade PanIN lesions are common in the general population, especially with age. The vast majority of them never progress to invasive cancer. This means that the presence of a KRAS mutation in a precursor lesion does not, by itself, predict cancer — additional mutations and microenvironmental changes are needed. Understanding what drives some lesions to progress while most remain indolent is one of the major open questions in the field.
This research shapes how preclinical drug models are built
The genetically engineered mouse models used to test pancreatic cancer drugs — including models used in the preclinical development of KRAS-directed therapies — are designed based on precursor lesion biology. They are built to recapitulate the PanIN-to-cancer progression sequence, with KRAS mutation as the initiating event. Without precursor lesion biology, these models would not exist, and the preclinical evidence supporting drugs like daraxonrasib would be less robust.
Related case
Where this concept appears in TrialLineage
Daraxonrasib in pancreatic cancer
Pancreatic precursor lesion biology is the disease-level foundation in the scientific lineage behind daraxonrasib. It established why KRAS is central to pancreatic cancer — not as a coincidental mutation but as the molecular event at the root of the disease. The case page traces the full discovery chain, from oncogene discovery and signaling biology through disease research, structural insight, chemical biology, medicinal chemistry, and clinical translation.
Related concepts
Other scientific fields in the TrialLineage discovery chain.
About this page
This is a TrialLineage concept explainer. Concept pages provide plain-language background on the scientific fields, branch points, and discoveries that underlie specific clinical developments. They are designed to be read independently or as companions to case pages — helping a public audience understand the full discovery process behind a human-disease trial.